1. The Global Market for Pain Management Drugs and Devices
Report Details:
Published:January 2013
No. of Pages: 221
Price: Single User License – US$5450
REPORT HIGHLIGHTS
This report provides:
•An overview of the global market for pain management drugs, which will address acute vs.
chronic pain, treatments, and issues facing healthcare workers.
•Analyses of global market trends, with data from 2012, and projections of compound annual
growth rates (CAGRs) through 2017.
•Examination of product categories, use of products, and the competitive landscape.
•Coverage of several significant market trends, including undertreatment issues, professional
issues, managed care pain issues, trends in new therapies, product pipelines, generic
participation, pain research, drug delivery, and patent expirations.
•Discussion of new regulatory requirements.
•Comprehensive company profiles of major players in the industry.
REPORT SCOPE
INTRODUCTION
STUDY GOALS AND OBJECTIVES
This BCC Research report, The Global Market for Pain Management Drugs and Devices, provides
an overview of products included in this market, and detailed analyses of markets and competitive
environments. The study includes information about significant products, players, issues and
trends, regulatory issues, and other information affecting the pain management industry.
REASONS FOR DOING THE STUDY
This study will provide the reader with the knowledge to adequately view and assess pain
management and the problems that the healthcare industry faces as well as provide insights into
the market potentials. This covers a wide variety of treatments and products that many people
worldwide rely on.
SCOPE AND FORMAT
This BCC Research report is designed to be a helpful business tool that will provide a thorough
evaluation of the markets for pain management. The geographical scope of this study is global
with a U.S. emphasis. This study will address acute versus chronic pain, treatments, and
regulatory issues facing healthcare workers. Also provided is detailed information based on
product categories, use of products, forecasts, and competitive analyses.

2. The report identifies two general segments of pain management:
•Pharmaceuticals.
•Devices.
Within the pharmaceuticals segment several sub-segments are discussed in detail
including:
•Narcotic pain management.
•Non-narcotic pain management.
•Antimigraine treatments.
•Anesthetics.
•Other drugs (including fibromyalgia treatments).
The device segment covers several product lines and specifically targets the largest
product segments including:
•TENS and neuromuscular stimulators.
•Spinal cord stimulators.
•Other products (including electromagnetic therapies and other treatments).
Each market segment provides detailed information based on product categories, product use,
forecasts, and competitive analyses.
METHODOLOGY
The information for this BCC report was obtained through primary and secondary data-collection
methods. Primary methods included interviews with approximately 35 key executives, physicians,
nurses, product managers, and other professionals involved in the pain treatment industry.
Secondary methods included published literature in the area of pain management, investment
reports, company literature, and various related journals.
Market data for this report pertains to the global market and uses U.S. dollars at the
manufacturers’ level. The base year of the report is 2012, with historical data provided for 2008
through 2011, and forecast data provided through 2017. Historical, base year and forecast data
are provided for each market segment of the report. Growth rates are determined through a
compilation of data, including past trends, future trends, demographics, incidence, mortality,
products in research and development, and current product growth, etc. Competitor market share
estimates are provided for each market segment for the 2012 base year.
Get your copy of this report @
http://www.reportsnreports.com/reports/213310-the-global-market-for-pain-management-drugs-and-devices.html
Major points covered in Table of Contents of this report include
TABLE OF CONTENTS
Chapter- 1: INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE AND FORMAT
METHODOLOGY
ANALYST CREDENTIALS

3. RELATED BCC STUDIES
BCC ON-LINE SERVICES
DISCLAIMER
Chapter- 2: SUMMARY
OVERVIEW
GENERAL PAIN TERMINOLOGY
MAJOR MARKETS SUMMARY
MARKET TRENDS
COMPETITORS
Chapter- 3: INDUSTRY OVERVIEW
HISTORY OF PAIN AND PAIN TREATMENT
HOW PAIN IS DIAGNOSED
HOW PAIN IS TREATED
Chapter- 4: INDUSTRY TRENDS
OVERVIEW
UNDERTREATMENT ISSUES
TREATMENT OF PAIN AND ISSUES FACING THE PROFESSIONAL SEGMENT
ACCESS TO CARE
PUBLIC HEALTHCARE SYSTEMS AROUND THE WORLD
MANAGED CARE PAIN MANAGEMENT ISSUES
FDA APPROVAL REQUIREMENTS FOR PAIN THERAPIES
DRUG DELIVERY SYSTEMS
Chapter- 5: TREATING PAIN
PHARMACEUTICAL PAIN MANAGEMENT
OVER-THE-COUNTER PAIN MANAGEMENT PRODUCTS
PAIN MANAGEMENT DEVICES
PAIN MANAGEMENT PROCEDURES: STEROIDS, ENDOSCOPY, FLUOROSCOPY
ALTERNATIVE METHODS OF PAIN MANAGEMENT
PAIN MANAGEMENT SERVICES AND ORGANIZATIONS
Chapter- 6: PRESCRIPTION PAIN MANAGEMENT MARKET SIZE AND ANALYSIS
TOTAL MARKET
PRESCRIPTION PAIN MARKETS BY PRODUCT TYPE
MARKET PARTICIPANTS
FUTURE MARKET ANALYSIS
Chapter- 7: PAIN MANAGEMENT DEVICE MARKET SIZE AND ANALYSIS
TOTAL PAIN MANAGEMENT DEVICE MARKET
PAIN MARKETS BY PRODUCT TYPE
MARKET PARTICIPANTS
FUTURE MARKET ANALYSIS
Chapter- 8: TOTAL MARKET SUMMARY
TOTAL PAIN MANAGEMENT MARKET
MARKET PERCENTAGE BY PRODUCT TYPE

4. MARKETS BY WORLD REGION
Chapter- 9: INDUSTRY DEVELOPMENTS
TIMELINE OF RECENT EVENTS AND DEVELOPMENTS
THE PIPELINE
NEW DEVELOPMENTS IN BREAKTHROUGH CANCER PAIN
NEW DEVELOPMENTS IN TREATING NEUROPATHIC PAIN
DEVELOPMENTS IN OPIOID-INDUCED CONSTIPATION AND REDUCED COMPLIANCE
FUTURE OF PAIN RESEARCH
PATIENT OUTCOMES RESEARCH
SELECTED PAIN-RELATED ACQUISITIONS AND ALLIANCES
DRUG PATENTS FOR SELECTED THERAPIES
Chapter- 10: COMPANY PROFILES
PHARMACEUTICAL AND DEVICE PAIN MANAGEMENT MANUFACTURERS
ABBOTT LABORATORIES
ASTRAZENECA
BAXTER INTERNATIONAL INC.
DJO GLOBAL, INC.
ELI LILLY & CO.
ENDO PHARMACEUTICALS, INC.
GLAXOSMITHKLINE
JOHNSON & JOHNSON
MEDTRONIC, INC.
MERCK & CO. INC.
NOVARTIS INTERNATIONAL AG
PFIZER
PURDUE PHARMACEUTICALS LP
ST. JUDE MEDICAL, INC.
Chapter- 11: APPENDIX I: SELECTED PAIN MANAGEMENT CLINICS-UNITED STATES-BY
STATE
ALABAMA PAIN CLINICS
CALIFORNIA PAIN CLINICS
COLORADO PAIN CLINICS
DELAWARE PAIN CLINICS
FLORIDA PAIN CLINICS
HAWAII PAIN CLINICS
IOWA PAIN CLINICS
MAINE PAIN CLINICS
NEVADA PAIN CLINICS
OREGON PAIN CLINICS
PENNSYLVANIA PAIN CLINICS
RHODE ISLAND PAIN CLINICS
SOUTH DAKOTA PAIN CLINICS

5. TEXAS PAIN CLINICS
WASHINGTON PAIN CLINICS
Chapter- 12: APPENDIX II: GLOBAL SELECTED PAIN MANAGEMENT CLINICS, BY
COUNTRY
ARGENTINA PAIN CLINICS
AUSTRALIA PAIN CLINICS
BRAZIL PAIN CLINICS
GERMANY PAIN CLINICS
INDIA PAIN CLINICS
ITALY PAIN CLINICS
SINGAPORE PAIN CLINICS
UNITED KINGDOM PAIN CLINICS
Chapter- 13: APPENDIX III: U.S. PAIN SOCIETIES AND ASSOCIATIONS
Chapter- 14: APPENDIX IV: INTERNATIONAL ASSOCIATIONS AND ORGANIZATIONS
Chapter- 15: APPENDIX V: COMPANY NAMES AND ADDRESSES
PAIN MANAGEMENT PHARMACEUTICAL MANUFACTURERS
LIST OF TABLES
Summary Table : GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES
MARKET, 2012 AND 2017
Table 1 : OBJECTIVE SIGNS OF PAIN
Table 2 : ESTIMATED GLOBAL POPULATION AND ANNUAL GROWTH BY SELECTED AGE
GROUP AND SELECTED YEARS, THROUGH 2030
Table 3 : GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015
Table 4 : GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010
Table 5 : SEVERE HEADACHE OR MIGRAINE, LOW BACK PAIN, AND NECK PAIN AMONG
ADULTS 18 YEARS OF AGE AND OVER*, 2005-2009
Table 6 : ESTIMATED* PREVALENCE/INCIDENCE OF CONDITIONS AFFECTING THE
WORLDWIDE ORTHOPEDIC INDUSTRY, AVERAGE FIGURE, 2008-2010
Table 7 : CANCER PAIN MEDICATION
Table 8 : ESTIMATED HIV REPORTED CASES BY REGION, 2011
Table 9 : BURN CLASSIFICATIONS
Table 10 : BIRTH RATES AND BIRTHS BY COUNTRY, 2010 ESTIMATES
Table 11 : U.S. SURGICAL PROCEDURES
Table 12 : SELECT SURGICAL PROCEDURES FOR GERMANY, UNITED KINGDOM, AND
FRANCE
Table 13 : PAIN BY SELECTED CATEGORY AND GENDER IN THE 18+ U.S. POPULATION*
Table 14 : AVAILABILITY OF EDUCATION IN PAIN MANAGEMENT BY SELECT
REGION/COUNTRY
Table 15 : TOTAL NUMBER OF ABUSE TREATMENT FACILITIES AND CLIENTS, 2000–2010
Table 16 : BENEFITS OF PRESCRIPTION MONITORING PROGRAMS FOR MEDICAL BOARDS
Table 17 : STATES WITH ELECTRONIC PRESCRIPTION MONITORING PROGRAMS
Table 18 : STATE CONTROLLED SUBSTANCES SCHEDULING AUTHORITIES AND OTHER

6. CONTACT INFORMATION
Table 19 : NURSE CONTINUING EDUCATION REQUIREMENTS FOR PAIN MANAGEMENT,
BY REQUIRING STATE
Table 20 : PHYSICIANS PER 1,000 POPULATION BY YEAR AND COUNTRY
Table 21 : NUMBER OF PHYSICIAN PER 100,000 RESIDENT POPULATION, UNITED STATES,
2009
Table 22 : AVAILABILITY OF INJECTABLE MORPHINE BY COUNTRY
Table 23 : AVAILABILITY OF ORAL MORPHINE IN HOSPICE-TYPE SETTINGS BY COUNTRY
Table 24 : WORLD HEALTH ORGANIZATION RANKING OF HEALTHCARE SYSTEMS, TOP 50
(2000)
Table 25 : HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY COUNTRY, 1980 TO 2010
Table 26 : HOSPITAL USAGE STATISTICS, AVERAGE 2000-2010
Table 27 : LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID PRODUCTS
REQUIRED TO HAVE AN OPIOID REMS, BRAND NAME PRODUCTS
Table 28 : LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID PRODUCTS
REQUIRED TO HAVE AN OPIOID REMS, GENERIC NAME PRODUCTS
Table 29 : LIST OF TRANSMUCOSAL IMMEDIATE-RELEASE FENTANYL PRODUCTS
REQUIRED TO HAVE TIRF REMS ACCESS PROGRAM
Table 30 : LIST OF MARKETED ACETAMINOPHEN-CONTAINING PRESCRIPTION
PRODUCTS
Table 31 : ADVANTAGES OF IONTOPHORETIC DRUG DELIVERY
Table 32 : RECENT FDA APPLICATIONS/APPROVALS, JANUARY 2010-OCTOBER 2012
Table 33 : MOST COMMONLY USED GENERAL ANESTHETIC AGENTS
Table 34 : ACETAMINOPHEN AND ACETAMINOPHEN COMBINATION PRODUCTS
Table 35 : ASPIRIN AND ASPIRIN COMBINATION PRODUCTS
Table 36 : IBUPROFEN AND IBUPROFEN COMBINATION PRODUCTS
Table 37 : KETOPROFEN PRODUCTS
Table 38 : OTC NONSTEROID ANTI-INFLAMMATORIES
Table 39 : ANTI-MIGRAINE PRODUCTS
Table 40 : TOPICAL ANESTHETIC PRODUCTS
Table 41 : UNITED STATES: ADULTS 18 YEARS AND OVER WHO USED COMPLEMENTARY
AND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY TYPE AND THERAPY,
2002-2012
Table 42 : HOSPICE STATISTICS, PATIENTS BY CHARACTERISTICS, 2009 AND 2010
Table 43 : HOSPICE STATISTICS, PATIENTS BY PRIMARY DIAGNOSIS
Table 44 : NHPCO COMMITTEES AND TASK FORCES
Table 45 : ESTIMATED NUMBER OF REGISTERED HOSPITALS BY SELECTED COUNTRY,
2010 ESTIMATES
Table 46 : TOTAL NUMBER OF REGISTERED U.S. HOSPITALS BY TYPE, 2010
Table 47 : GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS MARKET AT
MANUFACTURERS’ SALES LEVELS, THROUGH 2017
Table 48 : PRESCRIPTION NARCOTIC AND NON-NARCOTIC MANUFACTURER MARKET

7. SHARE BY REVENUE, 2012
Table 49 : PRESCRIPTION ANTI-MIGRAINE DRUG MANUFACTURER MARKET SHARE BY
REVENUE, 2012
Table 50 : PRESCRIPTION ANESTHETIC MANUFACTURER MARKET SHARE BY REVENUE,
2012
Table 51 : GLOBAL PAIN MANAGEMENT DEVICES MARKET BY PRODUCT TYPE, THROUGH
2017
Table 52 : GLOBAL NEUROMUSCULAR STIMULATOR/TENS—ELECTROTHERAPY
DEVICES—MANUFACTURER MARKET SHARE, 2012
Table 53 : GLOBAL SPINAL CORD STIMULATOR MANUFACTURER MARKET SHARE, 2012
Table 54 : PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES MARKET BY REVENUE,
THROUGH 2017
Table 55 : PERCENT DISTRIBUTION OF THE GLOBAL PAIN MANAGEMENT MARKET BY
SEGMENT, 2012
Table 56 : DISTRIBUTION OF GLOBAL PAIN MANAGEMENT REVENUES BY REGION, 2012
Table 57 : SELECTED PAIN-MANAGEMENT DRUG PIPELINES
Table 58 : U.S. PATENT EXPIRATION DATES FOR SELECT PAIN DRUGS
Table 59 : FIRST TIME PRESCRIPTION GENERIC PAIN MANAGEMENT AND APPROVALS,
JANUARY 2004-OCTOBER 2012
LIST OF FIGURES
Summary Figure : GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES
MARKET, 2012 AND 2017
Figure 1 : PAIN-MANAGEMENT TECHNIQUES
Figure 2 : ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED
YEARS, 2000-2030
Figure 3 : GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND PROJECTED 2015
Figure 4 : GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010
Figure 5 : GLOBAL CANCER DEATHS BY TYPE, 2008
Figure 6 : SEVERE HEADACHE OR MIGRAINE, LOW BACK PAIN, AND NECK PAIN AMONG
ADULTS 18 YEARS OF AGE AND OVER*, 2005-2009
Figure 7 : ESTIMATED* PREVALENCE/INCIDENCE OF CONDITIONS AFFECTING THE
WORLDWIDE ORTHOPEDIC INDUSTRY, AVERAGE FIGURE 2008–2010
Figure 8 : CAUSES OF CANCER PAIN
Figure 9 : ADULT PREVALENCE RATE, 2011
Figure 10 : BURN PAIN MANAGEMENT APPROACH
Figure 11 : BIRTH RATES AND BIRTHS BY COUNTRY, 2010 ESTIMATES
Figure 12 : PAIN BY SELECTED CATEGORY AND GENDER IN THE 18+ U.S. POPULATION*
Figure 13 : TOTAL NUMBER OF ABUSE TREATMENT FACILITIES, 2000–2010
Figure 14 : TOTAL NUMBER OF ABUSE TREATMENT CLIENTS, 2000–2010
Figure 15 : PHYSICIANS PER 1,000 POPULATION BY COUNTRY, 2010*
Figure 16 : NUMBER OF PHYSICIANS PER 100,000 RESIDENT POPULATION, UNITED
STATES 2009

8. Figure 17 : HOSPITAL USAGE STATISTICS
Figure 18 : UNITED STATES: ADULTS 18 YEARS AND OVER WHO USED COMPLEMENTARY
AND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY TYPE AND THERAPY,
2002-2012
Figure 19 : TOTAL HOSPICE PATIENTS SERVED BY YEAR, 2006-2010
Figure 20 : TOTAL HOSPICE PATIENTS BY GENDER, 2009 AND 2010
Figure 21 : TOTAL HOSPICE PATIENTS BY AGE, 2009 AND 2010
Figure 22 : TOTAL HOSPICE PATIENTS BY PRIMARY DIAGNOSIS, 2009 AND 2010
Figure 23 : GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS MARKET AT
MANUFACTURERS’ SALES LEVELS, 2008-2017
Figure 24 : PRESCRIPTION NARCOTIC AND NON-NARCOTIC MANUFACTURER MARKET
SHARE BY REVENUE, 2012
Figure 25 : PRESCRIPTION ANTI-MIGRAINE DRUG MANUFACTURER MARKET SHARE BY
REVENUE, 2012
Figure 26 : PRESCRIPTION ANESTHETIC MANUFACTURER MARKET SHARE BY REVENUE,
2012
Figure 27 : GLOBAL PAIN MANAGEMENT DEVICES MARKET BY PRODUCT TYPE, 2008-2017
Figure 28 : GLOBAL NEUROMUSCULAR STIMULATOR/TENS—ELECTROTHERAPY
DEVICES—MANUFACTURER MARKET SHARE, 2012
Figure 29 : GLOBAL SPINAL CORD STIMULATOR MANUFACTURER MARKET SHARE, 2012
Figure 30 : PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES MARKET BY REVENUE,
2008-2017
Figure 31 : PERCENT DISTRIBUTION OF THE GLOBAL PAIN MANAGEMENT MARKET BY
SEGMENT, 2012
Figure 32 : PERCENTAGE DISTRIBUTION OF GLOBAL PAIN MANAGEMENT SHARES BY
REGION, 2012
Contact: sales@reportsandreports.com for more information.